Charlie is a member of the firm’s Intellectual Property practice group. Charlie counsels clients in protecting and evaluating their intellectual property assets, from enforcing or protecting intellectual property rights through patent litigation, to prosecuting patents before the U.S. Patent and Trademark Office and protecting those intellectual property interests using the America Invents Act post-grant patent review process before the Patent Trial and Appeal Board. Charlie also assists clients with analyzing inventions for patentability opinions and patents for invalidity and noninfringement opinions. He also advises companies in the negotiation and drafting of agreements, including for the licensing, purchase, and sale of intellectual property assets.
While earning his law degree, Charlie was Business Manager of the University of Cincinnati Law Review, and a Founding Leader of the University of Cincinnati Intellectual Property & Computer Law Journal. He was also awarded the Gustavus Henry Wald Memorial Prize for Contracts, and was a member of the National Asian Pacific American Bar Association.
Charlie received his B.S. in bioengineering at Rice University. At Rice University, Charlie worked in the laboratory of Dr. Antonios Mikos developing polymer-controlled release systems for human growth hormones. As an undergrad, Charlie was awarded the George R. Brown Engineering Research Grant for his work. After graduation, Charlie continued working in the Mikos lab for 3 years, continuing his research on polymer control release systems and bone tissue engineering.
In 2023, Charlie was one of seven NGE attorneys to receive the Award for Excellence in Pro Bono Service from the U.S. District Court for the Northern District of Illinois and the Chicago Chapter of the Federal Bar Association.
- Pfizer Inc. et al. v. Zenara Pharma Private Limited – counsel for Defendant, Zenara Pharma Private Limited in Hatch-Waxman litigation involving Zenara’s Abbreviated New Drug Application for tafamadis (61 mg) capsules.
- Actelion Pharmaceuticals Ltd. v. Gland Pharma Limited – counsel for Defendant, Gland Pharma Limited in Hatch-Waxman litigation involving Gland’s Abbreviated New Drug Application for epoprostenol sodium for injection (1.5 mg/vial and 0.5 mg/vial)
- InfoRLife SA and WG Critical Care, LLC v. Hikma Pharmaceuticals USA, Inc. – counsel for Hikma in Hatch-Waxman litigation concerning Hikma’s Abbreviated New Drug Application for midazolam 0.9% sodium chloride (50 mg/50 ml and 100mg/100 ml) solution, for intravenous use. InforRLife’s case was dismissed with prejudice, and Hikma launched its product.
- Best Lawyers: Ones to Watch in America, "Intellectual Property Law," since 2022
Bar Admissions
- Illinois
- Ohio
- U.S. Patent and Trademark Office
Court Admissions
- U.S. District Court for the Northern District of Illinois
- U.S. District Court for the Southern District of Ohio